The estimated Net Worth of Olsen Per Wold is at least $14.3 Million dollars as of 10 January 2023. Mr. Wold owns over 22,027 units of Gilead Sciences stock worth over $13,842,925 and over the last 15 years he sold GILD stock worth over $0. In addition, he makes $449,977 as Independent Director at Gilead Sciences.
Sign up
Mr. Olsen GILD stock SEC Form 4 insiders trading
Per has made over 9 trades of the Gilead Sciences stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 22,027 units of GILD stock worth $1,782,865 on 10 January 2023.
The largest trade he's ever made was buying 55,000 units of Gilead Sciences stock on 13 June 2022 worth over $92,950. On average, Per trades about 5,271 units every 133 days since 2010. As of 10 January 2023 he still owns at least 171,027 units of Gilead Sciences stock.
You can see the complete history of Mr. Wold stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Per Wold-Olsen biography
Per Wold-Olsen serves as Independent Director of the Company. Mr. Wold-Olsen has served as the Chair of Gilead’s Health Policy Advisory Board since 2007. From 2005 to 2006, he served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S and Oncopeptides AB. In addition, he is the Chairman of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria.
What is the salary of Per Olsen?
As the Independent Director of Gilead Sciences, the total compensation of Per Olsen at Gilead Sciences is $449,977. There are 10 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.
How old is Per Olsen?
Per Olsen is 72, he's been the Independent Director of Gilead Sciences since 2010. There are 1 older and 24 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
What's Per Olsen's mailing address?
Olsen's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.
Insiders trading at Gilead Sciences
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger und John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
What does Gilead Sciences do?
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
What does Gilead Sciences's logo look like?
Complete history of Mr. Wold stock trades at Amarin Corp und Gilead Sciences
Gilead Sciences executives and stock owners
Gilead Sciences executives and other stock owners filed with the SEC include:
-
Daniel O'Day,
Chairman of the Board, Chief Executive Officer -
Johanna Mercier,
Chief Commercial Officer -
Daniel P. O'Day,
Chairman & CEO -
Andrew Dickinson,
Chief Financial Officer, Executive Vice President -
Brett Pletcher,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Johanna Mercier,
Chief Commercial Officer -
Dr. Merdad V. Parsey M.D., Ph.D.,
Chief Medical Officer -
Merdad Parsey,
Chief Medical Officer -
Brett A. Pletcher,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Andrew D. Dickinson,
Exec. VP & CFO -
Per Wold-Olsen,
Independent Director -
Richard Whitley,
Independent Director -
Kelly Kramer,
Independent Director -
Kevin Lofton,
Lead Independent Director -
Harish Manwani,
Independent Director -
Jacqueline Barton,
Independent Director -
Sandra Horning,
Independent Director -
Anthony Welters,
Director -
Javier Rodriguez,
Director -
Michael Quigley,
Senior Vice President - Research Biology -
Linda Higgins,
Senior Vice President - Head of External Innovation -
Jyoti Mehra,
Executive Vice President of Human Resources -
Dr. Linda Slanec Higgins Ph.D.,
Sr. VP & Head of External Innovation -
Jyoti K. Mehra,
Exec. VP of HR -
Deborah H. Telman,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Dr. Diana M. Brainard M.D.,
Sr. VP of HIV & Emerging Viral Infections -
Dr. Taiyin Yang,
Exec. VP of Pharmaceutical Devel. & Manufacturing -
Jacquie Ross C.F.A.,
VP of Investor Relations -
Diane E. Wilfong,
Sr. VP, Corp. Controller & Chief Accounting Officer -
John Francis Cogan,
Director -
John W Madigan,
Director -
Robin L Washington,
SVP, CFO -
Norbert W Bischofberger,
SVP, Research -
James R Meyers,
SVP Comm Ops North America -
Nicholas G Moore,
Director -
Gayle E Wilson,
Director -
Kevin Young,
EVP, Commercial Operations -
Laura Hamill,
EVP, Worldwide Commercial Ops -
Carla A Hills,
Director -
Etienne Davignon,
Director -
Paul Rutherford Carter,
EVP Commercial Ops -
John C Martin,
President and CEO -
John F Milligan,
EVP, Chief Financial Officer -
John G Mc Hutchison,
Chief Scientific Off/HeadR&D -
James M Denny,
Director -
Gordon Earle Moore,
Director -
Kristen Metza,
SVP, Human Resources -
Gregg H Alton,
SVP, General Counsel -
Paul Berg,
Director -
Louis G Lange,
EVP Cardiovascular Therapeutic -
Taiyin Yang,
SVP, Pharm Dev & Mfg -
William A Lee,
SVP Research and PPD -
Anthony Caracciolo,
SVP -
Caroline Dorsa,
SVP, Chief Financial Officer -
John J Toole,
SVP -
George P Shultz,
Director -
Alan Bruce Montgomery,
SVP, Respiratory Therapeutics -
Michael K Inouye,
SVP -
Mark L Perry,
EVP Operations -
Cordell W Hull,
Director -
Diane E. Wilfong,
SVP, Controller & CAO -
Sandra Patterson,
SVP, Controllership -
Jeffrey Bluestone,
Director -
Deborah H Telman,
EVP, Corporate Affairs & GC -
Ted W Love,
Director